Peer-Reviewed Publication
Cancers (Basel)2026;18(11)May 25, 2026Journal Article
Prognostic Significance of Inflammatory Biomarkers in First-Line Immunotherapy for Metastatic Melanoma: Multicentric Study.
Branko Dujovic1,2, Aleksandar Popovic3, Amina Jalovcic Suljevic4, Bojana Cikota-Aleksic5, Mirjana Balic3, Igor Salatic1,2, Jovana Pavlica1,2, Philipp Schnecko6, Tanja Mesti7, Muamer Terzo4, Emina Bicakcic Filipovic4, Lidija Kandolf1,2
1Clinic for Dermatovenerology, Military Medical Academy, University of Defense, 11000 Belgrade, Serbia.
2Faculty of Medicine, Military Medical Academy, University of Defense, 11000 Belgrade, Serbia.
3Clinic for Oncology, Clinical Centre of Niš, 18000 Niš, Serbia.
4Clinic of Oncology, Clinical Center University of Sarajevo, 71000 Sarajevo, Bosnia and Herzegovina.
5Centre for Clinical Pharmacology, Military Medical Academy, 11000 Belgrade, Serbia.
6Alcedis, a HUMA Company, 35394 Giessen, Germany.
7Institute of Oncology, 1000 Ljubljana, Slovenia.
Abstract
Background/Objectives: This study evaluates the prognostic value of baseline inflammatory biomarkers, neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), monocyte-to-lymphocyte ratio (MLR), lymphocyte-to-monocyte ratio (LMR), systemic immune-inflammation index (SII), and pan-immune-inflammation value (PIV) in advanced cutaneous melanoma treated with first-line immunotherapy.…
Create a free account to keep reading
Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.
Want unlimited research access? See Pro plans